These data were combined into a single data set for analyses. A total of 1,342 records (0.43%) were deleted from the final analytic data set because of invalid site/histology combinations based on a review by the CBTRUS consulting neuropathologist, or because of reclassification based on adjudication of multiple records. Of these, 131 cases had bilateral acoustic neuromas in which the records were consolidated. The final analytic data set included 311,202 records from 49 population-based central cancer registries.
Background
The Central Brain Tumor Registry of the United States (CBTRUS) is a unique professional research organization that focuses exclusively on providing quality statistical data on population-based primary brain and CNS incident tumors in the United States. CBTRUS is currently the only population-based site-specific registry in the United States that works in partnership with a public surveillance organization, the National Program of Central Registries (NPCR), and from which data are directly received under a special agreement. This agreement permits transfer of data through the NPCR-CSS Submission Specifications mechanism, 1 the system utilized for collection of central (state) cancer data as mandated in 1992 by Public Law 102-515, the Cancer Registries Amendment Act.
2 CBTRUS combines the NPCR data with data from the SEER program 3 which was established for national cancer surveillance in the early 1970s. Working with these premier surveillance organizations enables CBTRUS to report high quality data on brain and CNS tumors that are useful to the communities it serves.
Since 1995, CBTRUS has self-published fourteen reports that have contributed to the surveillance of brain and CNS tumors in the United States. As a result of partnering with the Society for Neuro-Oncology (SNO) 4 , this fifteenth CBTRUS report is the first to be published as a supplement to Neuro-Oncology, the official journal of SNO and marks an historic milestone for both organizations.
CBTRUS was incorporated as a nonprofit 501(c)3 organization with a founding and sustaining grant from the Pediatric Brain Tumor Foundation in 1992 following a two -year study conducted by the American Brain Tumor Association to determine the feasibility of a central registry for all primary brain and CNS tumor cases in the United States. Until that time, standard data reporting in the United States had been limited to only malignant cases. Non -malignant brain tumors, those classified as having a benign or uncertain behavior, however, may, and often do, impose similar costs to society in terms of medical care, case fatality, and lost productivity as do malignant brain tumors. In addition, as molecular markers have been discovered, it has become clear that certain non -malignant brain tumors may become malignant over time.
Passed in 2002, the Benign Brain Tumor Cancer Registries Amendment Act (Public Law 107 -260) 5 expanded the collection of primary brain and CNS tumor incidence data by the NPCR to include non-malignant brain and CNS tumors having International Classification of Diseases for Oncology Third Edition (ICD-O-3) 6 codes beginning with the 2004 diagnosis year. All central (state) cancer registries now include these data in their collection practices. Starting in 2004, Uniform Data Standards (UDS) as directed by the North American Association of Cancer Registries (NAACCR) 7 , an umbrella organization for tumor registries, governmental agencies, professional associations and private groups, guide the collection of required information on non-malignant brain and CNS tumors; in 2005, the UDS for the collection of malignant brain and CNS tumors were revised. The Multiple Primary and Histology Coding Rules for malignant and non-malignant brain and CNS tumors have been undergoing revision in 2012 under the leadership of SEER.
The CBTRUS database contains the largest aggregation of population-based data on the incidence of all primary brain and CNS tumors in the United States. This report represents a dramatic increase in population coverage (approximately 97% from the initial CBTRUS Reports). The central cancer registries receive populationbased, standardized data from all healthcare data sources primarily through certified tumor registrars. Along with the UDS, there are quality control checks and a system for rating each central registry to further insure that these data are reported as accurately and completely as possible. These individuals and organizations provide the high quality data that are the foundation of the CBTRUS statistical reports and scientific activities.
This statistical report continues the past efforts that CBTRUS has made to provide population-based incidence rates for all primary brain and CNS tumors by histology, age, gender, race, and Hispanic ethnicity. As in previous reports, these data have been organized by clinically relevant histological groupings that are useful for surveillance. The information is important for allocation and planning of specialty health -care services, in the planning of disease prevention and control programs, and in research activities. These data may lead to clues that will stimulate research into the causes of this terrible disease.
In 2012, the CBTRUS staff in collaboration with three neuropathologists, Drs. Janet Bruner (University of Texas M.D. Anderson Medical Center), Roger McLendon (Duke University) and Tarik Tihan (University of California at San Francisco) revised the CBTRUS Histology Grouping Scheme to reflect the 2007 WHO Classification of Tumours of the Central Nervous System. 8 CBTRUS will continue to update its grouping scheme to reflect state-of-the-art classification for brain and CNS tumors mindful that any future revisions will incorporate accepted ICD-O coding. CBTRUS will continue to share its expertise and to work cooperatively with other surveillance organizations as well as brain tumor clinicians and researchers to assure that primary brain and CNS tumors are collected and reported as accurately and completely as possible.
Technical Notes

Data Collection
CBTRUS does not collect data directly from patient's medical records. As noted, data for CBTRUS analyses come from NPCR and SEER programs. By law, cancer and benign brain tumors are reportable diseases, and central cancer registries in states are mandated to collect pertinent information on their residents, collate these data, and provide data files to NPCR and SEER. State central cancer registries (including the District of Columbia) play an essential role in the collection process, diagrammatically presented as follows.
CBTRUS obtained incidence data from 49 populationbased cancer registries (44 NPCR and 5 SEER) that include cases of malignant and non-malignant (benign and uncertain) primary brain and CNS tumors. It should be noted that metastatic tumors including those found in the brain and CNS are not collected by surveillance organizations in the United States. Data were requested for all newly-diagnosed primary malignant and Anatomic Location of Tumor Sites.-Various terms are used to describe the regions of the brain and central nervous system. The sites referred to in this report are broadly based on the categories and site codes defined in the SEER Site/Histology Validation List. 11 Tumors include olfactory tumors of the nasal cavity in addition to brain tumors located in sites included in the standard definition from the Consensus Conference on Brain Tumor Definition for Registration. 10 According to the standard definition from the Consensus Conference, reportable primary brain-related tumors (intracranial and central nervous system tumors) are all primary tumors, irrespective of histology and behavior, occurring in the following sites: brain; meninges; pineal gland; pituitary gland and craniopharyngeal duct; and spinal cord, cranial nerves, and other parts of the central nervous system. As per the site definition outlined by the Consensus Conference, brain lymphomas coded to any of the brain or CNS site codes listed above are included in the CBTRUS report. The group of tumors known as spinal cord tumors is coded to the following sites: spinal meninges, spinal cord, and cauda equina, and is highlighted in this report.
Statistics by ICD-O-3 primary sites are grouped in the following manner: the frontal lobe (C71.1); temporal lobe (C71.2); parietal lobe (C71.3); and occipital lobe (C71.4) are grouped together. Cerebrum (C71.0), ventricle (C71.5), cerebellum (C71.6), and brain stem (C71.7) are each grouped independently. Overlapping lesions of the brain, as well as brain sites not otherwise specified (NOS), are defined by ICD-O site codes C71.8 -C71.9. The cranial nerve category (C72.2 -C72.5) includes the olfactory nerve, optic nerve, acoustic nerve, and other cranial nerves. The spinal cord (C72.0) and cauda equina (C72.1) are grouped together. Overlapping lesions of the brain and central nervous system, as well as nervous system sites not otherwise specified (NOS), are defined by ICD-O site codes C72.8 -C72.9. The meninges (C70.0 -C70.9) include the cerebral meninges and spinal meninges. Pituitary tumors (C75.1 -C75.2) include tumors located in the pituitary gland and craniopharyngeal duct. Pineal tumors (C75.3) include tumors located in the pineal gland. In this report, tumors located in the nasal cavity (C30.0) are olfactory tumors (defined by ICD-O-3 histology codes 9522 and 9523).
Measurement Methods.-Counts, means, rates, ratios, proportions, and other relevant statistics were calculated using SPSS and/or SEER*Stat statistical software. 12, 13 Statistics are suppressed when counts are fewer than 16 within a cell. However, the data in the suppressed cells are included in the counts and rates for the totals.
Population data for each geographic region were obtained from the SEER program website 14 for the purpose of rate calculation. The estimates adjusted for the impact of the Katrina and Rita hurricanes on affected state populations were used in the data analyses for the statistics presented in this report.
Age-adjusted incidence rates and 95% confidence intervals 15 for malignant and non-malignant tumors and for selected histology groupings by gender, race, Hispanic ethnicity, and pediatric, young adult, and adult age groups were estimated. Age-adjustment was based on five-year age groupings and standardized to the Year 2000 U.S. standard population. Age-specific incidence rates by five-year age groups were also calculated. The age distribution of the 2000 U.S. standard population is shown in Appendix A. Combined populations for the regions included in this report are shown in Appendix B and Appendix C.
CBTRUS presents statistics on the pediatric age group 0-19 years in order to include and describe specific brain and CNS tumor patterns in age groups 0-4, 5-9, 10-14 as well as 15-19 years. However, the 0-14 year age group is a standard age category for childhood cancer used by other cancer surveillance organizations and has been included in this report for consistency and comparison purposes. Race categories in this report are all races, white, black, American Indian/Alaskan Native (AIAN), and Asian Pacific Islander (API). Other race: unspecified and unknown race are included in all race statistics. Hispanic ethnicity was defined using the NAACCR Hispanic Identification Algorithm, version 2, data element, which utilizes a combination of cancer registry data fields (Spanish/Hispanic Origin data element, birthplace, race, and surnames) to directly and indirectly classify cases as Hispanic or nonHispanic. 16 Trends across annual incidence rates were not estimated because a timeframe of five years for both malignant and non-malignant tumors as presented in this report is not sufficient to detect a real change in the rate pattern with any degree of confidence.
Brain Tumor Definition Differences.-It should be noted that NPCR, SEER, and NAACCR report brain tumors differently than CBTRUS. The definition of brain and CNS tumors used by these organizations (in their published incidence and mortality statistics) includes tumors located in the brain, meninges, and other central nervous system tumors (C70.0 -9, C71.0 -9, and C72.0 -9), but excludes lymphoma and leukemia histologies (9590 -9989) from all brain and CNS sites. NPCR and SEER include separate tables for malignant and non -malignant brain and CNS tumors reflecting the 2002 Consensus Conference 10 definition in their respective publications. With the inclusion of nonmalignant brain tumors, an increase in incidence rates may result, especially for the following histology groups and subgroups: (groups) tumors of meninges; tumors of cranial and spinal nerves; tumors of the sellar region; and (subgroups) unique astrocytoma variants; ependymal tumors; choroid plexus; neuronal and mixed neuronal-glial tumors; tumors of the pineal region; nerve sheath tumors; meningioma; mesenchymal tumors; other neoplasms related to the meninges; germ cell tumors; tumors of the pituitary; craniopharyngioma; hemangioma; neoplasm, unspecified; and all other.
In contrast, the CBTRUS reports data on all tumor morphologies located within the Consensus Conference site definition including the leukemia and lymphoma histologies Central Nervous System 8 as having uncertain behavior (ICD-0-3 behavior code of 1)] in their malignant (ICD-0-3 behavior code of 3) brain tumor data and statistics. In support of consistency within cancer surveillance reporting, the CBTRUS categorizes pilocytic astrocytomas in the malignant tumor category to enhance comparability of rates to those reported by NPCR, SEER, and NAACCR, especially for comparison of childhood brain and CNS tumor rates. It is important to understand these differences in definition, as they influence the direct comparison of published rates.
Estimation of Expected Numbers of Brain and CNS Tumors in 2012 and 2013.-Estimated numbers of expected malignant and non -malignant brain and CNS tumors were calculated for diagnosis years 2012 and 2013. The age-specific rate method was utilized to project 2012 and 2013 estimates of all primary brain and CNS tumors using the CBTRUS 2005 -2009 age-sex-race-specific brain tumor incidence rates for a group by the age-sex-race-specific population projections for that group. Projected population estimates for 2012 and 2013 were derived for the 50 states and District of Columbia using the US Census Bureau 2000-2009 population data (seer.cancer.gov/popdata/ index.html).
14 Estimation of Mortality Rates for Underlying Cause from Brain and CNS Tumors.-Age-adjusted mortality rates for deaths resulting from all brain and CNS tumors were calculated using SEER Stat 7.0.9.
12,17 The underlying mortality data were provided to the SEER program by the National Center for Health Statistics (NCHS) (www.cdc.gov/nchs). In addition to total age-adjusted rate for the United States, age-adjusted rates are presented by gender and state.
Estimation of Survival Rates.-SEER*Stat 7.0.9 statistical software was used to estimate one-through ten-year relative survival rates for primary malignant brain tumor cases diagnosed between 1995-2009 in eighteen SEER areas. 12, 18 This software utilizes life-table (actuarial) methods to compute survival estimates and accounts for current follow-up. The traditional cohort analysis of survival rates was utilized for the survival estimates presented in this report. Survival was estimated for brain (C71.0-C71.9), meninges (C70.0-C70.9), spinal cord, cranial nerves, and other parts of the central nervous system (C72.0-C72.9), pituitary and pineal glands (C75.1-C75.3), and olfactory tumors of the nasal cavity [C30.0 (9522-9523)]. Lymphomas and leukemias (morphology codes 9590-9989) and meningiomas (9530-9539) are included from all brain and CNS sites. Second or later primary tumors, cases diagnosed at autopsy, cases in which race or sex is coded as other or unknown, and cases known to be alive but for whom follow-up time could not be calculated were excluded from the SEER survival data analyses.
Data Interpretation.-The CBTRUS works diligently to support the broader surveillance efforts aimed at improving the collection and reporting of primary brain and CNS tumors. The central cancer registry data provided to NPCR and SEER and, subsequently, to CBTRUS vary from year-to-year due to ongoing updates in collection and data refinement aimed to improve completeness and accuracy. The data presented in this report must be interpreted within this surveillance framework as well as taking into account the information provided in the technical notes. Therefore, it is important to note that data from previous CBTRUS Reports cannot be compared to data in CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2005 -2009 .
Random fluctuations in average annual rates are usual especially for rates based on small incidence counts. The CBTRUS policy to suppress data presentation for cells with counts of less than 16 is consistent with the NPCR policy. The rationale for this policy is that rates produced with small counts are unreliable. The suppression of data with counts of fewer than 16 is more than adequate to protect confidentially given the CBTRUS data set is an aggregate of 48 states and the District of Columbia for 2005 -2009. Delays in reporting and late ascertainment are a reality and a known issue influencing registry completeness and, consequently, rate underestimations -especially for more recent data collection years. 19 CBTRUS also recognizes that the problem may be even more likely to occur in the reporting of non-malignant brain and CNS tumors, where reporting often comes from nonhospital based sources and mandated collection is relatively recent (2004) .
Reporting from Veteran's Health Administration (VHA) hospitals, the sole source of data for cancer cases diagnosed among Veterans served by those institutions, affects completeness of data. Cancer cases from VHA facilities account for at least three percent and possibly as much as eight percent of all cancer cases diagnosed among men. VHA policy that went into effect in 2007 restricting Veterans' health data sharing has resulted in the underreporting of cancer incidence data for diagnosis years 2005 through 2007. Since late 2008, VHA facilities and states with central cancer registries have been working to establish data transfer agreements that correct the problem to assure more complete ascertainment of national cancer incidence including brain and CNS tumor incidence data used in CBTRUS statistical reports. 20 CBTRUS editing practices conducted yearly aim to refine the data for accuracy and clinical relevance should also be recognized in interpreting these report data. Exclusion of site and histology combinations considered to be invalid by the consulting neuropathologists may have the impact of conservatively underestimating the incidence of brain and CNS tumors. Editing changes also incorporate updates to the cancer registration coding rules that influence case ascertainment and data collection. For example, beginning in 2004, some brain and CNS site codes were reconsidered as paired sites, that is having a tumor on the left and right Table 5 ).
Overall Incidence Rates.-The overall average annual age-adjusted incidence rate for 2005 -2009 for primary brain and CNS tumors was 20.59 per 100,000. The overall incidence rate was 5.13 per 100,000 for children 0 -19 years of age (4.97 per 100,000 for children less than 15 years), and 26.81 per 100,000 for adults (20+ years). The overall incidence rates of tumors by behavior and age group (0 -19 years and 20+ years) are shown in Incidence Rates by Central Cancer Registry, Age, and Behavior.-The overall average annual age-adjusted incidence rates by central cancer registry, age group, and behavior are presented in Table 6 . The overall average annual age-adjusted incidence rates of all primary brain and CNS tumors (malignant and non-malignant) for each individual central cancer registry ranged from 15.78 to 26.39 per 100,000. In addition, the average annual age-adjusted incidence rates of all primary malignant brain and CNS tumors ranged from 4.95 to 8.97 per 100,000, and the average annual age-adjusted incidence rates of all primary non -malignant brain and CNS tumors ranged from 8.90 to 19.02 per 100,000. Among adults 20 years of age and older, the central cancer registry -specific incidence rates ranged from 5.80 to 11.70 per 100,000 for malignant tumors and from 11.94 to 25.94 per 100,000 for non-malignant tumors. For several central cancer registries, the numbers of non-malignant tumors in those less than 20 years of age were too small to report; the highest reported incidence rate was 4.09 per 100,000 for malignant tumors and 3.61 per 100,000 for non-malignant tumors among the age group. It is apparent that there is less variation by state in malignant tumor incidence rates as compared to incidence rates for tumors of non-malignant behavior, suggesting greater consistency in reporting of the malignant tumors. The central cancer registry and regional variations apparent in Table 6 , especially in reported incidence rates for the non -malignant tumors, likely reflects differences in reporting practices including case ascertainment. Improvements in standardization of brain and CNS tumor collection and reporting with time will allow observation of the true variation in the incidence of brain and CNS tumors among states. Many non -malignant brain and CNS tumors are not histologically confirmed, ie the percent of diagnostically confirmed non-malignant tumors is lower than the percent of diagnostically confirmed malignant tumors. A statistically significant negative correlation exists between the proportion of tumors with non -malignant behavior and the proportion of tumors diagnostically confirmed by central cancer registry for the data presented in Table 5 . Conversely, a statistically significant positive correlation is evident for the proportion of nonmalignant tumors with the proportion of radiographic diagnostic confirmations. Figure 3 . The most common tumor site is the meninges (35%). Twenty-one percent of tumors are located within the frontal, temporal, parietal, and occipital lobes of the brain. Cerebrum, ventricle, cerebellum, and brain stem tumors account for 7.5% of all tumors. The cranial nerves and the spinal cord/cauda equina account for 10% of all tumors. Together, the pituitary and pineal glands account for about 16% of tumors.
Olfactory tumors of the nasal cavity account for less than 1% of tumors.
The distribution by brain and CNS histology is shown in Figure 4 . The most frequently reported histology is the predominately non -malignant meningioma, which accounts for more than one-third of all tumors, followed by glioblastoma, a malignant brain tumor. Tumors of the pituitary and nerve sheath tumors combined account for about one-fourth of all tumors, the majority of which are non-malignant. Acoustic neuromas (defined by ICD-O-3 site code C72.4 and histology code 9560) account for 65% of all nerve sheath tumors (data not shown).
The broad category glioma represents approximately 30% of all tumors (Figure 4) . The distribution of tumors by site for glioma is shown in Figure 5 . About 60% of gliomas occur in the four lobes of the brain.
The distribution by specific histology for glioma is illustrated in Figure 6 . Glioblastoma accounts for the majority of gliomas, while astrocytoma and glioblastoma combined account for about three-fourths of gliomas. by site is shown in Figure 8 . Approximately 22% of tumors diagnosed in young adults are located within the frontal, temporal, parietal and occipital lobes of the brain. Cerebrum, ventricle, cerebellum and brain stem tumors combined account for about 12% of all young adult tumors. Tumors of the meninges represent 14%, while the cranial nerves and the spinal cord and cauda equina combined account for about 12%. Tumors located in the pituitary and pineal glands together account for about 32% of young adult tumors. The distribution by histology for young adults is also shown in Figure 8 . Over half of reported histologies for tumors diagnosed in those 20-34 years of age are the predominately non -malignant tumors of the pituitary (29%), meningioma (14%), and nerve sheath (9%). The broad category glioma accounts for 31% of all brain and CNS tumors and about 81% of malignant tumors in young adults.
Incidence Rates by Site and Gender.-Incidence counts and average annual age-adjusted rates for brain and CNS tumors by site and gender are provided in Table 7 . Incidence rates were highest for tumors located in the meninges (7.18 per 100,000), followed by tumors located in the four lobes of the brain, pituitary, other areas of the brain, cranial nerves, spinal cord/cauda equina, cerebellum, cerebrum, brain stem, ventricle, other nervous system and pineal gland. Incidence rates were lowest for olfactory tumors of the nasal cavity (0.04 per 100,000). By gender, incidence rates were statistically significantly higher in females than in males for tumors located in the meninges, pituitary, and cranial nerves. Males had statistically significantly higher incidence rates of tumors located in the four lobes of the brain, cerebrum, ventricle, cerebellum, brain stem, other brain, spinal cord and cauda equina, other nervous system, pineal and olfactory tumors of the nasal cavity compared to females.
Incidence Rates by Major Histology Groupings and Specific Histologies.- Tables 8 through 16 present incidence rates by major histology groupings and specific histologies. Among major histology groupings, incidence rates were highest for tumors of the meninges (7.49 per 100,000), followed by tumors of the neuroepithelial tissue (6.60 per 100,000 person -years), tumors of the sellar region (3.12 per 100,000) and tumors of the cranial and spinal nerves (1.70 per 100,000) ( Table 8) . Incidence rates also varied by specific brain and CNS histology (Table 8) . Incidence rates were highest for meningiomas (7.22 per 100,000), glioblastomas (3.19 per 100,000), tumors of the pituitary (2.94 per 100,000), and nerve sheath tumors (1.70 per 100,000). The incidence rate for glioma was 6.03 per 100,000, a major contributor to the magnitude of the neuroepithelial tissue rate (data not shown). Acoustic neuromas, included under tumors of cranial and spinal nerves, comprise the majority (65%; 1.10 per 100,000) of nerve sheath tumors (1.70 per 100,000) and account for 5% of all primary brain and CNS tumors (data not shown).
Incidence Rates by Behavior and Histology.-Brain and CNS tumor incidence rates by behavior (malignant and non-malignant) are presented in Table 8 . For those with malignant behavior, the incidence rate was highest for glioblastoma (3.19 per 100,000) followed by diffuse astrocytoma (0.58 per 100,000), and lymphoma (0.45 per 100,000. Meningioma (7.10 per 100,000), tumors of the pituitary (2.93 per 100,000), and nerve sheath (1.69 per 100,000) tumors were the nonmalignant histologies with the highest incidence rates. Median Age at Diagnosis.-The median age at diagnosis for all primary brain and CNS tumors is 59 years ( Incidence Rates by Gender and Histology.-Incidence rates by histology and gender are presented in Table 9 . Incidence rates for all primary brain and CNS tumors combined are higher among females (22.25 per 100,000 person -years) than males (18.80 per 100,000 person -years). The difference between these incidence rates is statistically significant. Incidence rates for tumors of the neuroepithelial tissue are 1.4 times greater in males as compared to females, while tumors of the meninges are 2.2 times greater in females as compared to males. Incidence rates for tumors of the neuroepithelial and tumors of the meninges were statistically significantly different between males and females. The incidence rate of gliomas is higher in males (7.16 per 100,000 person -years) than in females (5.06 per 100,000 person -years). Similar patterns were found for individual histologies with incidence rates higher in males, especially for germ cell tumors, most glial tumors, lymphomas, and embryonal tumors, or comparable between males and females, with the notable exception of meningiomas and tumors of the pituitary, which are more common in women. Incidence rate ratios (male: female) for selected histologies are shown in Figure 9 .
Incidence Rates by Race and Histology.-Incidence rates by histology and race are shown in Table 10 .
Incidence rates for all primary brain and CNS tumors combined are substantially and statistically significantly lower for race groups AIAN (13.15 per 100,000) and API (12.98 per 100,000) compared with whites (20.61 per 100,000) and blacks (20.12 per 100,000). Incidence rates for most histologies are statistically significantly higher for whites than black, AIAN, and API race groups. An exception is observed for meningioma, tumors of the pituitary, and craniopharyngioma where the rates for blacks significantly exceed those observed for white, AIAN, and API races. It should also be noted that the average annual incidence rate for tumors of the cranial and spinal nerves in the API group is statistically significantly higher than those rates observed for black or AIAN races. Incidence rate ratios (white: black) for selected histologies are shown in Figure 10 . Incidence rates for anaplastic astrocytoma, glioblastoma, oligodendroglioma, oligoastrocytic tumors, and nerve sheath tumors are two or more times greater in whites than in blacks. Incidence rates for pilocytic astrocytoma, ependymal tumors, embryonal tumors, lymphoma and germ cell tumors also are significantly higher among whites than blacks. In contrast, incidence rates for meningioma and tumors of the pituitary are statistically significantly higher among blacks than whites.
Incidence Rates by Hispanic Ethnicity and Histology.-Incidence rates by Hispanic ethnicity and histology are shown in Table 11 . The overall incidence rate for primary brain and CNS tumors among Hispanics is 19.36 per 100,000 and among non -Hispanics is 20.81 per 100,000. The difference between these two incidence rates is statistically significant, with rates among non-Hispanics exceeding those observed for Hispanics overall and for most histologies. Only the incidence Incidence Rates by Age and Histology.-The agespecific incidence rates by histology are presented in Table 12 . The incidence for all brain and CNS tumors is highest among the 85+ year olds (75.27 per 100,000) and lowest among children ages 0-19 years (5.13 per 100,000). However, the distribution patterns of histologies within age groups differ substantially as is apparent in Table 12 . For example, the incidence rates of pilocytic astrocytoma, germ cell tumors and embryonal tumors are higher in the younger age groups and decrease with advancing age. This is in contrast to the incidence rate of meningioma, which increases progressively with age. Age -specific incidence rates for selected histologies are graphically displayed in Figure 11 . Figure 12 shows the most common and second most common brain and CNS tumor histologies by age at occurrence.
Childhood Primary Brain and CNS Tumors: Incidence by Site, Histology, Gender, and Age
Childhood Brain Tumors.-Brain and CNS tumors are the second most common malignancy among children; leukemias as a group are the most common. 21, 22 However, brain and CNS tumors are the most common form of solid tumors in children. 21 Figure 13 . The largest percentage of childhood tumors (17%) are located within the frontal, temporal, parietal and occipital lobes of the brain. Cerebrum, ventricle, cerebellum, and brain stem tumors account for 6%, 6%, 16%, and 10% of all childhood tumors, respectively. The listing, Other Brain, account for 14% and tumors of the meninges represent 3% of all childhood tumors. The cranial nerves and the spinal cord and cauda equina account for 6% and 5%, respectively. Tumors located in the pituitary and pineal glands together account for about 16% of all childhood brain and CNS tumors. Figure 14 presents the most common brain and CNS histologies in children ages 0-14 years and adolescents ages 15-19 years. For children ages 0-14 years, pilocytic astrocytomas, embryonal tumors, and malignant glioma, NOS, account for 18%, 15%, and 14%, respectively. The most common histologies in adolescents ages 15 -19 years include tumors of the pituitary (23%) and pilocytic astrocytoma (11%) ( Figure 14 ). The broad category glioma accounts for 53% of tumors in children ages 0-14 years and 37% in adolescents ages 15 -19 years.
Childhood Incidence Rates by Histology and Gender.-The incidence rates of the most common childhood tumors by gender are shown in Table 13 . The overall incidence rate for childhood brain and CNS tumors (ages 0-19 years) is 5.13 per 100,000. Among major histology groupings, incidence rates were highest for tumors of the neuroepithelial tissue (3.51 per 100,000). Pilocytic astrocytoma (0.80 per 100,000), embryonal tumors (0.65 per 100,000), and glioma malignant, NOS (0.58 per 100,000) have the highest rates among individual histologies. Germ cell tumors are more than twice as common in males compared to females. Conversely, the incidence rate of tumors of the pituitary for females is more than two and one-half times the rate observed for males. Differences in incidence rates between males and females for ependymal tumors, embryonal tumors, germ cell tumors, and tumors of the pituitary are statistically significant. Due to small numbers for some tumors caution when interpreting and comparing incidence rates is required.
Childhood Incidence Rates by Histology and Race.- Table 14 shows incidence rates by histology and race for children ages 0-19 years. Incidence rates were highest among whites (5.31 per 100,000) compared with black (3.96 per 100,000), AIAN (3.40 per 100,000) or API (3.07 per 100,000) race groups. The observed overall incidence rate differences between whites and each of the three other race groups are statistically significant. Total brain and CNS tumor incidence rates between black and AIAN races are not significantly different. However, the total average annual incidence rate for the API race group is statistically significantly lower than the rate observed for black children ages 0-19 years. Children ages 0-19 years of API races have statistically significantly higher rates of germ cell tumors and cysts than either white or black races. Conversely, API incidence rate for tumors of the sellar region is statistically significantly lower than those observed for white, black, or AIAN race groups.
Childhood Incidence rates by Histology and Hispanic Ethnicity.-Incidence rates for children ages 0-19 years by Hispanic ethnicity are shown in Table 15 . The non-Hispanic rate (5.30 per 100,000) is statistically significantly higher than the observed rate for Hispanics (4.55 per 100,000). This difference is apparent for incidence rates of tumors of neuroepithelial tissue and tumors of cranial and spinal nerves. Conversely, incidence rates for tumors of the pituitary are statistically significantly higher among Hispanic children ages 0-19 years than their non-Hispanic counterparts.
Childhood Incidence Rates by Age and Histology.-The detailed age -specific incidence rates by histology for children age groups 0-4 years, 5-9 years, 10-14 years, 15-19 years, 0-19 years, and 0-14 years are shown in Table 16 . The overall incidence rates for age groups 0-4 years and 15-19 years statistically significantly exceeded those observed in age groups 5-9 years and 10-14 years. It should also be noted that individual histology distributions vary substantially within these childhood age groups. The incidence rates of pilocytic astrocytoma, malignant glioma NOS, ependymal tumors, choroid plexus tumors and embryonal tumors decrease with increasing age groups. Age -specific incidence rates for selected histologies are graphically shown in Figure 15 . The U-shaped overall incidence rate pattern across the four age group categories is apparent on the graph. Sharp declines in incidence rates between age groups for the broad gliomas and embryonal tumor histology groups are evident. The incidence decline rate for pilocytic astrocytoma is substantial from the 10-14 years to the 15-19 years age group. In contrast, ependymal tumor incidence rates are highest in the 0-4 years age group then decline and remain relatively stable across the 5-9 years, 10-14 years, and 15-19 years age groups. Childhood Incidence Rates by Histology Defined by ICCC.- Table 17 presents the CBTRUS childhood brain and CNS tumor data used for this report according to the International Classification of Childhood Cancer (ICCC) grouping system for pediatric cancers. 23 As shown, the Table 17 age group category total 0-19 age group count and age-specific and adjusted rates are equivalent to those presented throughout this report. However, the histology grouping scheme differences are apparent and reflect different approaches to the description of childhood brain and CNS tumors.
Mortality Rates, Expected Incidence, and Survival
Estimated Mortality Rates from Brain and CNS Malignant Tumors by State and Gender.- Table 18 shows average annual age-adjusted mortality rates from primary malignant brain and CNS tumors in the Table 20 . Individuals diagnosed from 1995 through 2009 with tumors located in the cerebrum, the frontal, temporal, parietal and occipital lobes of the brain, other brain, and other nervous system have poor short-and long-term survival rates.
In contrast, those with tumor locations in the cerebellum, spinal cord and cauda equina, cranial nerves, pituitary and pineal glands and nasal cavity are observed to have better survival outcomes with ten -year survival rates ranging from 60% to as high as more than 90% (cranial nerves).
Survival Rates for Malignant Brain and CNS Tumors
by Histology and Age.-Survival estimates for malignant brain tumors by histology and age at diagnosis are presented in Tables 21 and 22 . The one -through ten -year relative survival rates by histology are shown in Table 21 . The estimated five-and ten -year relative survival rates for malignant brain and CNS tumors are 33.8% and 28.0%, respectively. However, there is a large variation in survival estimates depending upon tumor histologies (Table 21 ). For example, five -year survival rates are 94% for pilocytic astrocytomas but are less than 5% for glioblastomas. Survival generally decreases with older age at diagnosis (Table 22) . Children and young adults generally have better survival outcomes for most histologies. Figure 4 ). Ninety -eight percent of meningiomas reported to CBTRUS had a non -malignant behavior code (Table 8) . Of the non-malignant meningiomas, 49% were histologically confirmed, while 49% were radiographically confirmed. Meningiomas are more common in older adults (Table 12 ) and are uncommon in children. The incidence of meningiomas increases with increasing age. The rates for meningiomas increase dramatically after age 65 and continue to be high even among the population aged 85 years and older (Table 12) . Meningiomas are more than twice as common in females as compared to males ( Table 9 ). The incidence of meningiomas is statistically significantly higher in blacks than whites (Table 10 ). As only malignant meningiomas were reported in the SEER database prior to 2004, insufficient time has passed to estimate 5-year survival for non-malignant meningiomas, and therefore, survival estimates were not generated for this report. However, information about meningioma survival estimates was obtained from a manuscript that used the National Cancer Data Base and showed the overall five -year survival rate for meningioma to be 69% (70% for benign and 55% for malignant).
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In addition, a recent study of 12,284 patients with a diagnosis of nonmalignant intracranial meningioma reported to SEER for diagnosis years 2004-2007 found that over 85% of patients survived three years after diagnosis, and resection was associated with improved survival.
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Glioblastomas are the second most frequently reported histology and the most common malignancy. They account for 16% of all primary brain tumors (Table 8 ; Figure 4 ). Glioblastomas are more common in older adults (Table 12 ) and are uncommon in children.
Glioblastomas comprise approximately 3% of all brain and CNS tumors reported among 0-19 year olds (Table 4 ). The incidence of glioblastomas increases with increasing age, with rates highest in the 75 to 84 years olds (Table 12 ). Glioblastomas are 1.6 times more common in males (Table 9 ). Glioblastomas are two to three times higher among whites as compared to black, AIAN and API race groups (Table 10 ). The relative survival estimates for glioblastoma are quite low; less than 5% of patients survived five years post diagnosis (Table 21 ). Glioblastoma survival estimates are somewhat higher for the small number of patients who are diagnosed under age 20 (Table 22) .
Concluding Comment
The CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2005 -2009 presents a comprehensive view of current population-based incidence and related surveillance measures on primary malignant and nonmalignant brain and CNS tumors collected and reported by central cancer registries that cover approximately 97% of the United States population. This report aims to serve as a useful resource for researchers, patient families as well as clinicians. In keeping with its mission, CBTRUS continually revises its reports mindful of the broader surveillance community in which it works while balancing the input it receives from the clinical and research community, especially those comments from neuropathologists. In this way, the CBTRUS facilitates communication between the cancer surveillance and the brain tumor research and clinical communities and contributes meaningful insight into the descriptive epidemiology of all primary brain and CNS tumors in the United States. 
Disclaimer
The Central Brain Tumor Registry of the United States (CBTRUS) is a not-for-profit corporation which gathers and disseminates epidemiologic data on primary brain and central nervous system tumors in order to facilitate research and establish awareness of the disease. CBTRUS makes no representations or warranties, and gives no other assurances or guarantees, express or implied, with respect to the accuracy or completeness of the data presented. The information provided in this report is not intended to assist in the evaluation, diagnosis or treatment of individual diseases. Persons with questions regarding individual diseases should contact their own physician to obtain medical assistance. The contents in this report are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention. 
